Tag: GlobeNewswire

• FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell disease
• FDA classified Agios’ response to the information request as a major amendment to the mitapivat sNDA, resulting in a three-month review extension
• Mitapivat sNDA was submitted under the FDA’s accelerated approval pathway and granted Priority Review, with an original PDUFA goal date of November 1, 2026
• Agios will continue its labeling discussions with the FDA as part of the ongoing sNDA review, including elements of a potential REMS

CAMBRIDGE, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease. The PDUFA goal date for this sNDA, which was submitted under the FDA’s accelerated approval pathway and granted Priority Review, is now February 1, 2027.

On October 9, 2026 – three weeks before the original PDUFA goal date for the sNDA – the FDA requested additional information to evaluate whether a Risk Evaluation and Mitigation Strategy (REMS) is necessary for mitapivat in sickle cell disease. On October 19, 2026, Agios submitted its response, which included approximately nine months of updated safety data through October 9, 2026, from the ongoing open-label extension periods of the RISE UP Phase 2 and Phase 3 trials. With this additional follow-up, there continue to be no cases of hepatocellular injury (HCI) among patients with sickle cell disease treated with mitapivat that show a pattern and severity similar to those observed in the clinical trials for mitapivat in adults with thalassemia. The benefit-risk profile of mitapivat in sickle cell disease remains unchanged. On October 28, 2026, the FDA informed Agios that the company’s response had been classified as a major amendment to the sNDA, resulting in a three-month review extension.

Agios will continue its labeling discussions with the FDA, including elements of a potential REMS, and will keep working closely with the agency to bring mitapivat to patients with sickle cell disease, a community with significant unmet need, as soon as possible.

“We have strong conviction in mitapivat’s potential to transform care for people living with sickle cell disease, grounded in the comprehensive data from the RISE UP clinical program and further supported by the additional data we submitted in response to the FDA’s recent request. The FDA granted this application Priority Review, underscoring the serious need in this disease, and that urgency has not changed,” said Brian Goff, Chief Executive Officer, Agios. “Sickle cell disease affects approximately 100,000 people in the U.S. and is the largest indication we have pursued for mitapivat, and we expect it to be a significant growth driver for Agios. We are launch-ready, building on our commercial infrastructure and the strong relationships we have established over several years with hematologists, sickle cell centers, and patients. We will continue to work expeditiously with the goal of bringing mitapivat to patients with sickle cell disease as soon as possible.”

The mitapivat sNDA is based on data from the global, randomized, double-blind, placebo-controlled RISE UP Phase 2 and Phase 3 trials in patients aged 16 years or older with sickle cell disease. Mitapivat is currently approved in the U.S. for adult patients in two hemolytic anemias: pyruvate kinase (PK) deficiency (2022) and thalassemia (2025).

About U.S. Accelerated Approval
The U.S. Food and Drug Administration’s (FDA) accelerated approval pathway expedites the availability of medicines that can fill a medical need for a serious condition. U.S. accelerated approval is subject to the same rigorous FDA review standards as medicines reviewed through the traditional approval pathway. A confirmatory clinical trial to further demonstrate the medicine’s clinical benefit is required to convert the accelerated approval to a traditional approval, and this trial must be underway when the FDA makes its approval decision.

In July 2026, Agios dosed the first patient in the REIGNITE Phase 3 trial (NCT07656415), the confirmatory clinical trial required to be conducted under the U.S. accelerated approval pathway. This global trial is designed to demonstrate the clinical benefit of mitapivat on reducing transfusion burden in patients with sickle cell disease aged 12 years or older.

About Mitapivat in Sickle Cell Disease
Sickle cell disease is a rare, inherited blood disorder in which abnormal hemoglobin causes red blood cells to become rigid and sickle-shaped, leading to chronic hemolysis (red blood cell destruction) that contributes to severe anemia and progressive, life-threatening complications, including damage to the lungs, kidneys, and heart. Mitapivat is an oral medicine designed to enhance red blood cell energy by activating the pyruvate kinase (PK) enzyme, which can increase levels of adenosine triphosphate (ATP) and lower levels of 2,3-diphosphoglycerate (2,3-DPG). Mitapivat has a unique dual mechanism of action that activates two isoforms of the PK enzyme – PKR found in red blood cells and PKM2 found in organ tissues – and has shown the potential to address both chronic hemolysis and pathways involved with long-term organ damage.

About the RISE UP Phase 3 Trial
The global RISE UP Phase 3 trial (NCT05031780) was designed to evaluate the efficacy and safety of mitapivat in patients with sickle cell disease aged 16 years or older, representative of the global population. The trial design encompassed a 52-week, double-blind, randomized, placebo-controlled period, in which 207 participants were randomized 2:1 to receive oral mitapivat (100 mg) twice daily (n=138) or matched-placebo (n=69), followed by an open-label extension (OLE) period, during which all participants receive mitapivat.

To evaluate the effect of mitapivat on clinically relevant outcomes in sickle cell disease, the RISE UP Phase 3 trial design included two primary endpoints – hemoglobin response (≥1.0 g/dL increase from baseline in average hemoglobin from Week 24 through Week 52) and annualized rate of sickle cell pain crises – as well as five key secondary endpoints:

• Average change from baseline in hemoglobin concentration from Week 24 through Week 52
• Average change from baseline in indirect bilirubin from Week 24 through Week 52
• Average change from baseline in Patient Reported Outcome Measurement Information System Fatigue 13a (PROMIS Fatigue) Short Form scores from Week 24 through Week 52
• Annualized frequency of hospitalizations for sickle cell pain crises
• Average change from baseline in percent reticulocyte levels from Week 24 through Week 52

Of the 176 participants who completed the double-blind period of the trial, nearly all (n=174/176) entered the OLE period.

About PYRUKYND^® (mitapivat)
U.S. INDICATION
PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

U.S. IMPORTANT SAFETY INFORMATION
Acute Hemolysis: Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath.

Hepatocellular Injury in Another Condition: In patients with another condition treated with mitapivat at a higher dose than that recommended for patients with PK deficiency, liver injury has been observed. These events were characterized by a time to onset within the first 6 months of treatment with peak elevations of alanine aminotransferase of >5x upper limit of normal (ULN) with or without jaundice. All patients discontinued treatment with mitapivat, and these events improved upon treatment discontinuation.

Obtain liver tests prior to the initiation of PYRUKYND and monthly thereafter for the first 6 months and as clinically indicated. Interrupt PYRUKYND if clinically significant increases in liver tests are observed or alanine aminotransferase is >5x ULN. Discontinue PYRUKYND if hepatic injury due to PYRUKYND is suspected.

Adverse Reactions: The most common adverse reactions including laboratory abnormalities (≥10%) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.

Drug Interactions:

• Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.
• Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily.
• Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage.
• Sensitive CYP3A, CYP2B6, CYP2C Substrates Including Hormonal Contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.
• UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.
• P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.

Hepatic Impairment: Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment.

Please see full Prescribing Information for PYRUKYND.

About AQVESME^® (mitapivat)
U.S. INDICATION
AQVESME is indicated for the treatment of anemia in adults with alpha- or beta-thalassemia.

U.S. IMPORTANT SAFETY INFORMATION
BOXED WARNING: HEPATOCELLULAR INJURY

AQVESME can cause serious hepatocellular injury. Measure liver laboratory tests (ALT, AST, alkaline phosphatase and total bilirubin with fractionation) at baseline and every 4 weeks for 24 weeks and then as clinically indicated. Avoid use of AQVESME in patients with cirrhosis. Discontinue AQVESME if hepatic injury is suspected.
Because of the risk of hepatocellular injury, AQVESME is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the AQVESME REMS.

WARNINGS AND PRECAUTIONS

Hepatocellular Injury
AQVESME can cause hepatocellular injury. Avoid use of AQVESME in patients with cirrhosis. In patients with thalassemia treated with AQVESME, liver injury with and without jaundice has been observed within the first 6 months of exposure. Obtain liver tests (including ALT, AST, alkaline phosphatase, total bilirubin with fractionation) prior to the initiation of AQVESME, then every 4 weeks for the first 24 weeks, and as clinically indicated thereafter. Interrupt AQVESME if clinically significant increases in liver tests are observed or alanine aminotransferase is >5 times the upper limit of normal (ULN). Complete a comprehensive evaluation to rule out other causes of liver injury when drug-induced liver injury is suspected. Discontinue AQVESME if hepatocellular injury due to AQVESME is suspected.

Symptoms and signs of early liver injury may mimic those of thalassemia. Advise patients to report new or worsening symptoms of loss of appetite, nausea, right-upper-quadrant abdominal pain, vomiting, scleral icterus, jaundice, or dark urine while on AQVESME treatment.

During the double-blind period, 2 of 301 patients (0.66%) with thalassemia treated with AQVESME experienced adverse reactions suggestive of hepatocellular injury. Three additional patients experienced adverse reactions suggestive of hepatocellular injury during the open-label extension periods after switching from placebo to AQVESME. Of these 5 patients, 2 had serious liver injury requiring hospitalization, including 1 patient who developed jaundice (peak bilirubin 32 mg/dL). Another patient developed jaundice (peak bilirubin 4 mg/dL) without requiring hospitalization. These reactions were characterized by a time to onset within the first 6 months of treatment with peak elevations of alanine aminotransferase of >5×ULN with or without jaundice. All patients discontinued treatment with AQVESME, and these reactions improved upon treatment discontinuation.

AQVESME REMS
AQVESME is available only through a restricted program under a REMS called the AQVESME REMS because of the risk of hepatocellular injury.

Adverse Reactions
The most common adverse reactions among patients taking AQVESME were headache and insomnia.

Drug Interactions

• Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.
• Moderate CYP3A Inhibitors: Avoid concomitant use.
• Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, see full Prescribing Information for recommended dosage for drug interactions with moderate CYP3A inducers.
• Sensitive CYP3A Substrates, including hormonal contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.
• CYP2B6, CYP2C, and UGT1A1 Substrates: Monitor patients for efficacy of the substrates with narrow therapeutic index.
• P-gp Substrates: Monitor patients for adverse reactions of the substrates with narrow therapeutic index.

Hepatic Impairment
Avoid use of AQVESME in patients with cirrhosis (Child-Pugh Class A, B, or C).

Please see full Prescribing Information for AQVESME, including Boxed Warning.

About Agios: Fueled by Connections to Transform Rare Diseases™
At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.

Available Information about Agios
To achieve broad dissemination, Agios may disclose information to the public through a variety of disclosure channels including press releases, SEC filings, and public conference calls and webcasts. Some of the information distributed through these disclosure channels may be considered material information. Investors and others should note that Agios plans to use its website (www.agios.com) as a distribution channel to announce and give notice of Agios’ upcoming events and presentations (including, but not limited to, presentations at medical or healthcare conferences). Such information, which may be deemed material, will be available on the Investors section of the company’s website under the “Events & Presentations” tab. In addition, you may sign up to automatically receive email alerts about Agios’ upcoming events and presentations (“Calendar Alerts”) by visiting the “Email Alerts” option under the “IR Resources” tab of the Investors section of the company’s website and submitting your email address.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of mitapivat; Agios’ communications with the FDA with respect to its sNDA for mitapivat; its planned further engagements with FDA; and other statements regarding Agios’ strategic plans, objectives and focus. The words “anticipate,” “expect,” “goal,” “hope,” “milestone,” “plan,” “potential,” “possible,” “strategy,” “will,” “vision,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios’ product candidates will successfully continue. There can be no guarantee that any positive developments in Agios’ business will result in stock price appreciation. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation: risks and uncertainties related to the impact of pandemics or other public health emergencies to Agios’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios’ results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios’ ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios’ ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios’ ability to establish and maintain key collaborations; uncertainty regarding any royalty payments related to the sale of its oncology business or any milestone or royalty payments related to its in-licensing of AG-236 or cevidoplenib, and the uncertainty of the timing of any such payments; uncertainty of the results and effectiveness of the use of Agios’ cash and cash equivalents; and general economic and market conditions. These and other risks are described in greater detail under the caption “Risk Factors” included in Agios’ public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:
Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
morgan.sanford@agios.com

Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
eamonn.nolan@agios.com

RESTON, Va., Oct. 30, 2026 (GLOBE NEWSWIRE) — Lightbridge Corporation (“Lightbridge” or the “Company”) (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced that it has received a Notification of Patent Grant from the Korean Ministry of Intellectual Property (“MOIP”), formerly the Korean Intellectual Property Office, for Korean Patent Application No. 10-2025-7001591, titled “Nuclear Fuel Assembly.” The application covers 17 claims directed to a fuel assembly in which the fuel elements are arranged in a mixed grid pattern that combines two different grid patterns. The patent will be registered upon payment of the registration fee.

The allowed claims describe a fuel assembly in which the outermost fuel elements form a substantially circular perimeter, the bundle shape used in pressurized heavy water reactors, including CANDU-type designs. Each fuel element has a multi-lobed profile with spiral ribs, and the ribs of neighboring elements touch at intervals along the assembly length to help hold the elements in position. Dependent claims cover bundles of 19 and 61 fuel elements inside a circular or twelve-sided shroud, grid patterns that alternate along concentric circles, and assemblies that combine four-lobe Lightbridge fuel rods, conventional pelleted fuel rods, or burnable poison rods.

The application is a divisional in the same Korean patent family as the patent Lightbridge announced in August 2022, which required the mixed grid to pair a rectangular grid pattern with a triangular grid pattern. The newly allowed claims cover the mixed grid pattern itself, without requiring any particular grid shape, which gives Lightbridge broader protection in South Korea regarding how its fuel elements can be arranged within a bundle.

South Korea operates 26 reactors that supply about one-third of the country’s electricity, including three CANDU 6 pressurized heavy water reactors at the Wolsong site, according to the World Nuclear Association. The government’s 11th Basic Plan for Electricity Supply and Demand calls for nuclear power to rise from 30.7% of generation in 2023 to 35.2% in 2038, supported by two new large reactors.

“South Korea is one of the few countries that operates both pressurized water and pressurized heavy water reactors, and it builds and exports its own reactor designs, so patent coverage there supports both our light water and CANDU fuel designs,” said Seth Grae, Chairman and Chief Executive Officer of Lightbridge Corporation. “Our 2022 Korean patent protected one specific combination of rectangular and triangular grids. These claims broaden patent protection to include the mixed-grid approach.”

Lightbridge’s fuel technology is backed by an extensive worldwide patent portfolio spanning jurisdictions representing the majority of global nuclear generating capacity.

About Lightbridge Corporation 
Lightbridge Corporation (Nasdaq: LTBR) is focused on developing advanced nuclear fuel technology essential to delivering abundant, zero-emission, clean energy and providing energy security to the world. The Company is developing Lightbridge Fuel™, a proprietary next-generation nuclear fuel technology for existing light-water and pressurized heavy-water reactors, significantly enhancing reactor safety, economics, and proliferation resistance. The Company is also developing Lightbridge Fuel for new small modular reactors to deliver the same benefits, plus load-following with renewables, on a zero-carbon electric grid.

Lightbridge has entered into two long-term framework agreements with Battelle Energy Alliance, LLC, the United States Department of Energy’s operating contractor for Idaho National Laboratory, the United States’ lead nuclear energy research and development laboratory. DOE’s Gateway for Accelerated Innovation in Nuclear program has twice awarded Lightbridge to support the development of Lightbridge Fuel over the past several years. An extensive worldwide patent portfolio backs Lightbridge’s innovative fuel technology. Lightbridge is included in the Russell 2000®, Russell 3000®, and Solactive Global Uranium and Nuclear Components Total Return Indexes. For more information, please visit www.ltbridge.com.

To receive Lightbridge Corporation updates via e-mail, subscribe at https://www.ltbridge.com/investors/news-events/email-alerts  

Lightbridge is on YouTube. Subscribe to access past demonstrations, interviews, and other video content at https://www.youtube.com/@lightbridgecorporation

Lightbridge is on X (formerly Twitter). Sign up to follow @LightbridgeCorp at http://twitter.com/lightbridgecorp. 

Forward Looking Statements 

With the exception of historical matters, the matters discussed herein are forward-looking statements. These statements are based on current expectations on the date of this news release and involve a number of risks and uncertainties that may cause actual results to differ significantly from such estimates. The risks include, but are not limited to: Lightbridge’s ability to commercialize its nuclear fuel technology; the degree of market adoption of Lightbridge’s product and service offerings; Lightbridge’s ability to fund general corporate overhead and outside research and development costs; market competition; our ability to attract and retain qualified employees; dependence on strategic partners; demand for fuel for nuclear reactors; Lightbridge’s ability to manage its business effectively in a rapidly evolving market; the availability of nuclear test reactors and the risks associated with unexpected changes in Lightbridge’s fuel development timeline; the increased costs associated with metallization of Lightbridge’s nuclear fuel; public perception of nuclear energy generally; changes in the political environment; risks associated with war in Europe; changes in the laws, rules and regulations governing Lightbridge’s business; development and utilization of, and challenges to, Lightbridge’s intellectual property; risks associated with potential shareholder activism; potential and contingent liabilities; as well as other factors described in Lightbridge’s filings with the Securities and Exchange Commission (the “SEC”). Lightbridge does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise, except as required by law. Readers are cautioned not to put undue reliance on forward-looking statements. 

A further description of risks and uncertainties can be found in Lightbridge’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in its other filings with the SEC, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Statements,” all of which are available at http://www.sec.gov/ and www.ltbridge.com.  

Investor Relations Contact: 
Matthew Abenante, IRC 
Senior Director of Investor Relations & Capital Markets  
Tel: +1 (347) 947-2093  
ir@ltbridge.com

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:	Man Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:  Use a separate form for each offeror/offeree	Gamma Communications plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:  For an opening position disclosure, state the latest practicable date prior to the disclosure	29/10/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	0.25p ordinary
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	761,936	0.85
(2) Cash-settled derivatives:	427,097	0.47
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	1,189,033	1.33

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b) Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
0.25p ordinary	Equity swap	Reducing a long position	842	10.9404 GBP
0.25p ordinary	Equity swap	Reducing a long position	9,581	10.9252 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	30/10/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:	Man Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:  Use a separate form for each offeror/offeree	RHI Magnesita N.V.
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:  For an opening position disclosure, state the latest practicable date prior to the disclosure	29/10/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	YES Offeree: Vesuvius plc

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	€1 ordinary
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	1,173,190	2.47
(2) Cash-settled derivatives:	310,513	0.65
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	1,483,703	3.13

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
€1 ordinary	Purchase	5,848	26.9229 EUR
€1 ordinary	Purchase	2,589	26.9229 EUR

(b) Cash-settled derivative transactions

Class of relevant security

Product description e.g. CFD

Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	30/10/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

#FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:	Man Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:  Use a separate form for each offeror/offeree	Rotork Plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:  For an opening position disclosure, state the latest practicable date prior to the disclosure	29/10/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	0.5p ordinary
	Interests		Short positions
	Number	%		Number	%
(1) Relevant securities owned and/or controlled:
(2) Cash-settled derivatives:	16,021,985	1.96		11,213	0.00
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	16,021,985	1.96		11,213	0.00

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b) Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
0.5p ordinary	Equity Swap	Increasing a long position	24,848	4.9282 GBP
0.5p ordinary	Equity Swap	Increasing a long position	41,429	4.9282 GBP
0.5p ordinary	Equity Swap	Increasing a long position	26,722	4.9282 GBP
0.5p ordinary	Equity Swap	Increasing a long position	6,268	4.9282 GBP
0.5p ordinary	Equity Swap	Increasing a long position	358,934	4.9282 GBP
0.5p ordinary	Equity Swap	Increasing a long position	7,363	4.9282 GBP
0.5p ordinary	Equity Swap	Increasing a long position	87,883	4.9282 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	30/10/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:	Man Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:  Use a separate form for each offeror/offeree	Sthree plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:  For an opening position disclosure, state the latest practicable date prior to the disclosure	29/10/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	1p ordinary
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	6,859,795	5.64
(2) Cash-settled derivatives:	3,585,732	2.95	15,497	0.01
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	10,445,527	8.60	15,497	0.01

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
1p ordinary	Purchase	39,720	3.0220 GBP

(b) Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
1p ordinary	Equity swap	Reducing a long position	4,854	3.0367 GBP
1p ordinary	Equity swap	Reducing a long position	12,911	3.0367 GBP
1p ordinary	Equity swap	Reducing a long position	225	3.0367 GBP
1p ordinary	Equity swap	Reducing a long position	31,809	3.0367 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	30/10/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:	Man Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:  Use a separate form for each offeror/offeree	Vesuvius plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:  For an opening position disclosure, state the latest practicable date prior to the disclosure	29/10/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	YES Offeror: RHI Magnestia N.V.

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	10p ordinary
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	13,143,478	5.29
(2) Cash-settled derivatives:	395,857	0.15	499,224	0.20
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	13,539,335	5.45	499,224	0.20

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b) Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
10p ordinary	Equity Swap	Reducing a long position	8,148	4.7485 GBP
10p ordinary	Equity Swap	Reducing a long position	23,154	4.7485 GBP
10p ordinary	Equity Swap	Reducing a long position	124	4.7485 GBP
10p ordinary	Equity Swap	Reducing a long position	53,929	4.7485 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	30/10/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

INDIANAPOLIS, Oct. 30, 2026 (GLOBE NEWSWIRE) — Kite Realty Group (NYSE: KRG), a premier owner and operator of high-quality, open-air grocery-anchored shopping centers and vibrant mixed-use assets, reported today its operating results for the third quarter ended September 30, 2026. For the quarters ended September 30, 2026 and 2025, net loss attributable to common shareholders was $13.3 million, or $0.07 per diluted share, compared to $16.2 million, or $0.07 per diluted share, respectively. For the nine months ended September 30, 2026 and 2025, net income attributable to common shareholders was $159.4 million, or $0.78 per diluted share, compared to $117.8 million, or $0.54 per diluted share, respectively.

   Company raises 2026 FFO and Same Property NOI guidance ranges
   Executed over 1.2 million square feet of leasing volume
   Increased signed-not-open NOI pipeline to approximately $38.8 million
Received a credit rating upgrade to BBB+ from Fitch Ratings

“Third quarter results reflect exceptional tenant demand, the quality of our portfolio, and disciplined capital allocation,” said John A. Kite, Chairman and Chief Executive Officer. “We delivered 3.6% Same Property NOI growth and executed over 1.2 million square feet of leasing, including comparable blended lease spreads of 14.6%. This strong leasing volume increased our signed-not-open NOI pipeline to nearly $39 million and boosted our leased-to-occupied spread to an all-time high of 360 basis points. We continued to advance our capital allocation initiatives during the quarter while earning a BBB+ credit rating upgrade from Fitch, further validating the strength of our portfolio and balance sheet.”

Third Quarter 2026 Financial and Operational Results

• Generated Core FFO of the Operating Partnership of $107.0 million, or $0.52 per diluted share.
• Generated NAREIT FFO of the Operating Partnership of $107.9 million, or $0.53 per diluted share.
• Same Property NOI increased by 3.6%.
• Executed 160 new and renewal leases representing approximately 1.2 million square feet.
  • Blended cash leasing spreads of 14.6% on 129 comparable leases, including 33.7% on 30 comparable new leases, 18.3% on 43 comparable non-option renewals, and 7.6% on 56 comparable option renewals.
  • Blended cash leasing spreads of 26.2% for comparable new and non-option renewal leases.
• Operating retail portfolio annualized base rent (ABR) per square foot of $23.52 at September 30, 2026, a 6.4% increase year-over-year.
• Retail portfolio leased percentage of 95.3% at September 30, 2026, a 140-basis point increase year-over-year.
  • Anchor leased percentage of 96.9% at September 30, 2026, a 190-basis point increase year-over-year.
  • Small shop leased percentage of 92.7% at September 30, 2026, a 90-basis point increase year-over-year.
• Portfolio leased-to-occupied spread at period end of 360 basis points, which represents approximately $38.8 million of signed-not-open NOI.

Third Quarter 2026 Capital Allocation Activity

• As previously announced, sold one non-core asset – Tysons Corner in Vienna, VA – for $25.9 million.
  • Subsequent to quarter end, sold one non-core asset – Carillon medical office building in Largo, MD – for a gross sales price of $33.2 million.
• Acquired the fee interest in the land at Pelham Manor Shopping Plaza, an existing retail property in the New York metropolitan statistical area, for a gross purchase price of $52.0 million.
• Repurchased approximately 2.4 million common shares, at an average price of $26.61 per share, for $63.4 million.
  • In 2025 and to date in 2026, repurchased a total of approximately 22.0 million common shares, at an average price of approximately $24.46 per share, for $539.1 million.

Third Quarter 2026 Balance Sheet Overview

• As of September 30, 2026, the Company’s net debt to Adjusted EBITDA was 5.2x.
• As previously announced, on July 2, 2026, the Company’s operating partnership issued $345 million of 3.25% exchangeable senior notes due 2032, which included the full exercise of the initial purchasers’ $45 million overallotment option.
  • In connection with the issuance of the exchangeable notes, the Company entered into capped call transactions with an initial cap of $41.91 per share, compared with the exchangeable notes’ initial exchange price of approximately $35.40 per share. The Company used the majority of the proceeds, together with cash from its recent asset dispositions, to redeem the operating partnership’s $300 million principal balance of the 4.00% senior unsecured notes that were scheduled to mature on October 1, 2026.
• Repaid the $100 million principal balance of the 4.08% senior unsecured notes that matured on September 30, 2026.
• Fitch Ratings upgraded the Company’s corporate credit rating to BBB+ from BBB with a stable rating outlook.

Dividend

• On October 29, 2026, the Company’s Board of Trustees declared a fourth quarter 2026 dividend of $0.29 per common share. Total dividends declared for 2026 of $1.16 per common share represents a 5.5% increase year-over-year. The fourth quarter dividend will be paid on or about January 15, 2027, to shareholders of record as of January 9, 2027.

2026 Earnings Guidance
The Company expects to generate net income of $0.88 to $0.92 per diluted share in 2026. The Company is raising its 2026 Core FFO and NAREIT FFO guidance ranges to $2.08 to $2.12 per diluted share from $2.06 to $2.12 per diluted share, based, in part, on the following full year 2026 assumptions:

• 2026 Same Property NOI growth range of 3.40% to 3.90% (previously 3.00% to 4.00%).
• Bad debt reserve of 0.90% of total revenues at the midpoint.
• Interest expense, net of interest income, excluding unconsolidated joint ventures, of $116.4 million at the midpoint (previously $114.7 million).

The following table reconciles the Company’s 2026 net income guidance range to the Company’s 2026 NAREIT and Core FFO guidance ranges:

		Low			High
Net income		$0.88			$0.92
Gain on sales of operating properties, net			(0.44)			(0.44)
Gain on deconsolidation of joint venture			(0.29)			(0.29)
Impairment charges			0.18			0.18
Depreciation and amortization			1.75			1.75
NAREIT FFO		$2.08			$2.12
Non-cash items			0.00			0.00
Core FFO		$2.08			$2.12

Earnings Conference Call

Kite Realty Group will conduct a conference call to discuss its financial results on Friday, October 30, 2026, at 11:00 a.m. Eastern Time. A live webcast of the conference call will be available on KRG’s website at kiterealty.com or at the following link: KRG Third Quarter 2026 Webcast. The dial-in registration link is: KRG Third Quarter 2026 Teleconference Registration. In addition, a webcast replay link will be available on KRG’s website.

About Kite Realty Group

Kite Realty Group (NYSE: KRG) is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of open-air shopping centers and mixed-use destinations. The Company’s portfolio is concentrated in high-growth Sun Belt and select strategic gateway markets. Publicly listed since 2004, KRG brings more than six decades of experience in developing, operating, and investing in real estate, using a disciplined, hands-on approach to enhance portfolio quality and maximize long-term value for all stakeholders. As of September 30, 2026, the Company owned interests in 164 U.S. open-air shopping centers and mixed-use assets, comprising approximately 26.3 million square feet of gross leasable space. For more information, please visit kiterealty.com.

Connect with KRG: LinkedIn | X | Instagram | Facebook

Safe Harbor

This release, together with other statements and information publicly disseminated by us, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on assumptions and expectations that may not be realized and are inherently subject to risks, uncertainties and other factors, many of which cannot be predicted with accuracy and some of which might not even be anticipated. Future events and actual results, performance, transactions or achievements, financial or otherwise, may differ materially from the results, performance, transactions or achievements, financial or otherwise, expressed or implied by the forward-looking statements.

Risks, uncertainties and other factors that might cause such differences, some of which could be material, include but are not limited to: economic, business, banking, real estate and other market conditions, particularly in connection with low or negative growth in the U.S. economy as well as economic uncertainty (including from an economic slowdown or recession, federal government shutdown, disruptions related to tariffs and other trade or sanction issues, geopolitical instability, rising interest rates, inflation, unemployment, or limited growth in consumer income or spending); financing risks, including the availability of, and costs associated with, sources of liquidity; the Company’s ability to refinance, or extend the maturity dates of, the Company’s indebtedness; the level and volatility of interest rates; the financial stability of the Company’s tenants; the competitive environment in which the Company operates, including potential oversupplies of, or a reduction in demand for, rental space; acquisition, disposition, development and joint venture risks, including the ability to complete them on the terms and timing anticipated; property ownership and management risks, including the relative illiquidity of real estate investments, and expenses, vacancies or the inability to rent space on favorable terms or at all; the Company’s ability to maintain the Company’s status as a real estate investment trust for U.S. federal income tax purposes; potential environmental and other liabilities; impairment in the value of real estate property the Company owns; the attractiveness of our properties to tenants; the actual and perceived impact of e-commerce on the value of shopping center assets and changing demographics and customer traffic patterns; business continuity disruptions and a deterioration in our tenants’ ability to operate in affected areas or delays in the supply of products or services to us or our tenants from vendors that are needed to operate efficiently; risks related to our current geographical concentration of properties in the states of Texas, Florida, and North Carolina and the metropolitan statistical areas of New York, Atlanta, Seattle, Chicago, and Washington, D.C.; civil unrest, acts of violence, terrorism or war, acts of God, climate change, epidemics, pandemics, natural disasters and severe weather conditions, including such events that may result in underinsured or uninsured losses or other increased costs and expenses; changes in laws and government regulations, including governmental orders affecting the use of the Company’s properties or the ability of its tenants to operate, and the costs of complying with such changed laws and government regulations; possible changes in consumer behavior due to public health crises and the fear of future pandemics; our ability to satisfy environmental, social or governance standards set by various constituencies; insurance costs and coverage, especially in Florida and Texas coastal areas and North Carolina; risks associated with cyberattacks and the loss of confidential information and other business disruptions; risks associated with the use of artificial intelligence and related tools; other factors affecting the real estate industry generally; and other risks identified in reports the Company files with the Securities and Exchange Commission or in other documents that it publicly disseminates, including, in particular, the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in the Company’s quarterly reports on Form 10-Q. The Company undertakes no obligation to publicly update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

This Earnings Release also includes certain forward-looking non-GAAP information. These non-GAAP financial measures should be considered along with, but not as alternatives to, net income (loss) as a measure of our operating performance. Please see the following pages for the corresponding definitions and reconciliations of such non-GAAP financial measures.

Kite Realty Group Consolidated Balance Sheets (dollars in thousands) (unaudited)
	September 30, 2026				December 31, 2025
Assets:
Investment properties, at cost	$	6,869,869			$	7,003,479
Less: accumulated depreciation		(1,759,251	)			(1,656,191	)
Net investment properties		5,110,618				5,347,288
Cash and cash equivalents		32,542				36,761
Tenant and other receivables, including accrued straight-line rent of $74,817 and $70,940, respectively		131,237				127,865
Restricted cash and escrow deposits		124,527				441,605
Deferred costs, net		163,121				181,553
Prepaid and other assets		64,970				93,913
Investments in unconsolidated joint ventures		401,162				364,407
Assets associated with investment properties held for sale		—				71,105
Total assets	$	6,028,177			$	6,664,497
Liabilities and Equity:
Liabilities:
Mortgage and other indebtedness, net	$	2,807,320			$	3,025,478
Accounts payable and accrued expenses		178,079				221,118
Deferred revenue and other liabilities		170,079				221,813
Liabilities associated with investment properties held for sale		—				4,314
Total liabilities		3,155,478				3,472,723
Commitments and contingencies
Limited Partners’ interests in the Operating Partnership		129,456				116,245
Equity:
Common shares, $0.01 par value, 490,000,000 shares authorized, 197,966,711 and 208,979,900 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively		1,979				2,090
Additional paid-in capital		4,300,836				4,612,280
Accumulated other comprehensive income		18,576				23,079
Accumulated deficit		(1,578,846	)			(1,563,840	)
Total shareholders’ equity		2,742,545				3,073,609
Noncontrolling interests		698				1,920
Total equity		2,743,243				3,075,529
Total liabilities and equity	$	6,028,177			$	6,664,497

Kite Realty Group Consolidated Statements of Operations (dollars in thousands, except per share amounts) (unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Revenue:
Rental income	$	186,511			$	202,193			$	577,867			$	632,547
Other property-related revenue		1,248				1,477				4,173				4,312
Fee income		2,516				1,291				5,190				2,569
Total revenue		190,275				204,961				587,230				639,428
Expenses:
Property operating		27,653				28,536				87,264				87,243
Real estate taxes		23,666				25,678				72,968				80,090
General, administrative and other		15,041				14,183				43,534				39,831
Depreciation and amortization		79,655				89,370				243,750				285,488
Impairment charges		30,694				39,305				37,562				39,305
Total expenses		176,709				197,072				485,078				531,957
Other (expense) income:
Interest expense		(31,569	)			(33,162	)			(95,008	)			(100,168	)
Income tax expense of taxable REIT subsidiaries		(251	)			(106	)			(1,072	)			(315	)
Gain on sales of operating properties, net		2,341				5,742				90,068				108,855
Net gains from outlot sales		2,259				6,096				4,662				6,096
Gain on deconsolidation of joint venture		—				—				60,625				—
Equity in loss of unconsolidated joint ventures		(3,775	)			(4,619	)			(7,335	)			(8,464	)
Other income, net		3,805				1,750				9,546				6,978
Net (loss) income		(13,624	)			(16,410	)			163,638				120,453
Net loss (income) attributable to noncontrolling interests		322				203				(4,242	)			(2,612	)
Net (loss) income attributable to common shareholders	$	(13,302	)		$	(16,207	)		$	159,396			$	117,841
Net (loss) income per common share – basic	$	(0.07	)		$	(0.07	)		$	0.79			$	0.54
Net (loss) income per common share – diluted	$	(0.07	)		$	(0.07	)		$	0.78			$	0.54
Weighted average common shares outstanding – basic		199,097,852				219,408,533				202,314,395				219,652,052
Weighted average common shares outstanding – diluted		199,097,852				219,408,533				203,142,324				219,768,504

Kite Realty Group NAREIT Funds From Operations (“FFO”)(1) (dollars in thousands, except per share amounts) (unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Net (loss) income	$	(13,624	)		$	(16,410	)		$	163,638			$	120,453
Less: net income attributable to noncontrolling interests in properties		—				(82	)			(126	)			(233	)
Less: gain on sales of operating properties, net		(2,341	)			(5,742	)			(90,068	)			(108,855	)
Less: gain on deconsolidation of joint venture		—				—				(60,625	)			—
Add: impairment charges		30,694				39,305				37,562				39,305
Add: depreciation and amortization of consolidated and unconsolidated entities, net of noncontrolling interests		93,163				101,750				275,983				304,896
NAREIT FFO of the Operating Partnership(1)		107,892				118,821				326,364				355,566
Less: Limited Partners’ interests in FFO		(2,800	)			(2,569	)			(8,212	)			(7,498	)
FFO attributable to common shareholders(1)	$	105,092			$	116,252			$	318,152			$	348,068
FFO, as defined by NAREIT, per share of the Operating Partnership – basic	$	0.53			$	0.53			$	1.57			$	1.58
FFO, as defined by NAREIT, per share of the Operating Partnership – diluted	$	0.53			$	0.53			$	1.57			$	1.58
Weighted average common shares outstanding – basic		199,097,852				219,408,533				202,314,395				219,652,052
Weighted average common shares outstanding – diluted		199,199,751				219,531,606				202,410,018				219,768,504
Weighted average common shares and units outstanding – basic		204,405,613				224,258,121				207,539,183				224,386,126
Weighted average common shares and units outstanding – diluted		204,507,512				224,381,194				207,634,806				224,502,578
Reconciliation of NAREIT FFO to Core FFO(2)
NAREIT FFO of the Operating Partnership(1)	$	107,892			$	118,821			$	326,364			$	355,566
Add:
Amortization of deferred financing costs		2,220				1,856				5,877				5,251
Non-cash compensation expense and other		3,679				3,084				10,568				8,965
Less:
Straight-line rent – minimum rent and common area maintenance		2,850				3,789				7,970				9,202
Market rent amortization income		3,091				2,500				7,433				7,921
Amortization of debt discounts, premiums and hedge instruments		826				1,030				2,885				4,676
Core FFO of the Operating Partnership	$	107,024			$	116,442			$	324,521			$	347,983
Core FFO per share of the Operating Partnership – diluted	$	0.52			$	0.52			$	1.56			$	1.55

(1) “NAREIT FFO of the Operating Partnership” measures 100% of the operating performance of the Operating Partnership’s real estate properties. “FFO attributable to common shareholders” reflects a reduction for the redeemable noncontrolling weighted average diluted interest in the Operating Partnership.

(2) Includes the Company’s pro rata share from unconsolidated joint ventures.

NAREIT Funds From Operations (“FFO”) is a widely used performance measure for real estate companies and is provided here as a supplemental measure of our operating performance. The Company calculates FFO, a non-GAAP financial measure, in accordance with the best practices described in the April 2002 National Policy Bulletin of the National Association of Real Estate Investment Trusts (“NAREIT”), as restated in 2018. The NAREIT white paper defines FFO as net income (calculated in accordance with GAAP), excluding (i) depreciation and amortization related to real estate, (ii) gains and losses from the sale of certain real estate assets, (iii) gains and losses from change in control, and (iv) impairment write-downs of certain real estate assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity.

Considering the nature of our business as a real estate owner and operator, the Company believes that FFO is helpful to investors in measuring our operational performance because it excludes various items included in net income that do not relate to or are not indicative of our operating performance, such as gains or losses from sales of certain real estate assets that are excluded from FFO under the NAREIT definition and depreciation and amortization, which can make periodic and peer analyses of operating performance more difficult. FFO (a) should not be considered as an alternative to net income (calculated in accordance with GAAP) for the purpose of measuring our financial performance, (b) is not an alternative to cash flows from operating activities (calculated in accordance with GAAP) as a measure of our liquidity, and (c) is not indicative of funds available to satisfy our cash needs, including our ability to make distributions. The Company’s computation of FFO may not be comparable to FFO reported by other REITs that do not define the term in accordance with the current NAREIT definition or that interpret the current NAREIT definition differently than we do.

From time to time, the Company may report or provide guidance with respect to “FFO, as adjusted,” which removes the impact of certain non-recurring and non-operating transactions or other items the Company does not consider to be representative of its core operating results, including, without limitation, (i) gains or losses associated with the early extinguishment of debt, (ii) gains or losses associated with litigation involving the Company that is not in the normal course of business, (iii) merger and acquisition costs, (iv) the impact on earnings from significant and non-recurring employee severance costs and recruiting expenses, including sign-on bonuses and search fees, (v) the excess of redemption value over carrying value of preferred stock redemption, and (vi) the impact of prior period bad debt or the collection of accounts receivable previously written off (“prior period collection impact”), which are not otherwise adjusted in the Company’s calculation of FFO.

Core Funds From Operations (“Core FFO”) is a non-GAAP financial measure of operating performance that modifies FFO for certain non-cash transactions that result in recording income or expense and impact the Company’s period-over-period performance, including (i) amortization of deferred financing costs, (ii) non-cash compensation expense and other, (iii) straight-line rent related to minimum rent and common area maintenance, (iv) market rent amortization income, and (v) amortization of debt discounts, premiums and hedge instruments, and includes adjustments related to our pro rata share from unconsolidated joint ventures for these categories as applicable. The Company believes that Core FFO is useful to investors in evaluating the core cash flow-generating operations of the Company by adjusting for items that we do not consider to be part of our core business operations, allowing for comparison of core operating performance of the Company between periods. Core FFO should not be considered as an alternative to net income as an indicator of the Company’s performance or as an alternative to cash flow as a measure of liquidity or the Company’s ability to make distributions. The Company’s computation of Core FFO may differ from the methodology for calculating Core FFO used by other REITs and, therefore, may not be comparable to such other REITs.

Kite Realty Group
Same Property Net Operating Income (“NOI”)
(dollars in thousands)
(unaudited)
	Three Months Ended September 30,											Nine Months Ended September 30,
		2026				2025			Change				2026				2025			Change
Number of properties in Same Property Pool for the period(1)		157				157							157				157
Leased percentage at period end		95.2	%			94.4	%						95.2	%			94.4	%
Economic occupancy percentage at period end		91.5	%			91.7	%						91.5	%			91.7	%
Economic occupancy percentage(2)		91.3	%			91.1	%						91.1	%			91.4	%
Minimum rent	$	139,166			$	135,581						$	415,600			$	404,014
Tenant recoveries		40,226				37,994							122,725				115,216
Bad debt reserve		(1,628	)			(1,947	)						(4,685	)			(5,219	)
Overage rent		1,560				1,282							4,386				3,840
Other property-related revenue		896				789							2,630				2,212
Total revenue		180,220				173,699							540,656				520,063
Property operating		(25,027	)			(24,241	)						(75,801	)			(71,700	)
Real estate taxes		(23,176	)			(21,974	)						(69,363	)			(67,158	)
Total expenses		(48,203	)			(46,215	)						(145,164	)			(138,858	)
Same Property NOI(3)	$	132,017			$	127,484			3.6	%		$	395,492			$	381,205			3.7	%
Reconciliation of Same Property NOI to most directly comparable GAAP measure:
Net operating income – same properties	$	132,017			$	127,484						$	395,492			$	381,205
Net operating income – sold properties		152				18,700							15,697				74,230
Net operating income – non-same activity(4)		6,972				5,756							18,558				17,309
Less: KRG share of unconsolidated joint ventures included in Same Property NOI above		(2,701	)			(2,484	)						(7,939	)			(3,218	)
Net gains from outlot sales		2,259				6,096							4,662				6,096
Total property NOI		138,699				155,552			(10.8	%)			426,470				475,622			(10.3	%)
Fee income		2,516				1,291							5,190				2,569
General, administrative and other		(15,041	)			(14,183	)						(43,534	)			(39,831	)
Depreciation and amortization		(79,655	)			(89,370	)						(243,750	)			(285,488	)
Impairment charges		(30,694	)			(39,305	)						(37,562	)			(39,305	)
Interest expense		(31,569	)			(33,162	)						(95,008	)			(100,168	)
Income tax expense of taxable REIT subsidiaries		(251	)			(106	)						(1,072	)			(315	)
Gain on sales of operating properties, net		2,341				5,742							90,068				108,855
Gain on deconsolidation of joint venture		—				—							60,625				—
Equity in loss of unconsolidated joint ventures		(3,775	)			(4,619	)						(7,335	)			(8,464	)
Other income, net		3,805				1,750							9,546				6,978
Net loss (income) attributable to noncontrolling interests		322				203							(4,242	)			(2,612	)
Net (loss) income attributable to common shareholders	$	(13,302	)		$	(16,207	)					$	159,396			$	117,841

(1)   Same Property NOI excludes the following: (i) Chastain Market and Founders Square, which were acquired in May 2026, and Village Commons and Legacy West, which were acquired in January and April 2025, respectively; (ii) The Corner – IN, which was reclassified from active development into our operating portfolio in March 2025; (iii) Eastgate Crossing, which was reclassified from our operating portfolio in September 2025 due to significant disruption caused by severe flooding as a result of Tropical Storm Chantal; (iv) our active development projects at One Loudoun; (v) Edwards Multiplex – Ontario, which was reclassified from our operating portfolio into redevelopment in March 2023; (vi) properties sold or classified as held for sale during 2025 and 2026; and (vii) standalone office properties, including the Carillon medical office building.
(2)   Excludes leases that are signed but for which tenants have not yet commenced the payment of cash rent. Calculated as a weighted average based on the timing of cash rent commencement and expiration during the period.
(3)   Same Property NOI for all periods presented includes (i) 52% of the NOI from three previously wholly owned properties that were contributed to the Seed Asset Joint Venture in June 2025 and (ii) 55% of the NOI from the One Loudoun Phase 1 Apartments (which 55% represents the Company’s expected final ownership percentage) and excludes the results of the Company’s insurance captive.
(4)   Includes non-cash activity as well as NOI from properties not included in the Same Property Pool.

The Company uses NOI, a non-GAAP financial measure, to evaluate the performance of our properties. The Company also uses total property NOI, which is defined as NOI plus net gains from outlot sales. The Company defines NOI as income from our real estate, including lease termination fees received from tenants, less our property operating expenses. NOI excludes amortization of capitalized tenant improvement costs and leasing commissions and certain corporate-level expenses, including merger and acquisition costs. The Company believes that NOI is helpful to investors as a measure of our operating performance because it excludes various items included in net income that do not relate to or are not indicative of our operating performance, such as depreciation and amortization, interest expense, and impairment, if any.

The Company also uses same property NOI (“Same Property NOI”), a non-GAAP financial measure, to evaluate the performance of our properties. Same Property NOI is net income excluding properties that have not been owned for the full periods presented. Beginning in 2026, the Company revised its Same Property NOI definition to exclude the results of the Company’s insurance captive to more clearly reflect the performance of our core real estate portfolio. Same Property NOI also excludes (i) net gains from outlot sales, (ii) straight-line rent revenue, (iii) lease termination income in excess of lost rent, (iv) amortization of lease intangibles, (v) significant prior period expense recoveries and adjustments, if any, and (vi) income or expense associated with the Company’s captive insurance company. When the Company receives payments in excess of any accounts receivable for terminating a lease, Same Property NOI will include such excess payments as monthly rent until the earlier of the expiration of 12 months or the start date of a replacement tenant.

The Company believes that Same Property NOI is helpful to investors as a measure of our operating performance because it includes only the NOI of properties that have been owned for the full periods presented. The Company believes such presentation eliminates disparities in net income due to the acquisition or disposition of properties during the particular periods presented and thus provides a more consistent metric for the comparison of our properties. Additionally, because results from the Company’s insurance captive are driven by insurance underwriting, loss experience, and actuarial assumptions and therefore do not reflect the operating performance of our real estate properties, management believes excluding the impacts of the insurance captive improves transparency and comparability for the Company’s investors. Same Property NOI includes the results of properties that have been owned for the entire current and prior year reporting periods. Same Property NOI for all periods presented includes (i) 52% of the NOI from three previously wholly owned properties that were contributed to the Seed Asset Joint Venture in June 2025 and (ii) 55% of the NOI from the One Loudoun Phase 1 Apartments (which 55% represents the Company’s expected final ownership percentage) and excludes the results of the Company’s insurance captive.

NOI and Same Property NOI should not, however, be considered as an alternative to net income (calculated in accordance with GAAP) as an indicator of our financial performance. The Company’s computation of NOI and Same Property NOI may differ from the methodology used by other REITs and, therefore, may not be comparable to such other REITs.

When evaluating the properties that are included in the Same Property Pool, we have established specific criteria for determining the inclusion of properties acquired or those recently under development. An acquired property is included in the Same Property Pool when there is a full quarter of operations in both years subsequent to the acquisition date. Development and redevelopment properties are included in the Same Property Pool four full quarters after the properties have been transferred to the operating portfolio. A redevelopment property is first excluded from the Same Property Pool when the execution of a redevelopment plan is likely, and we (a) begin recapturing space from tenants or (b) the contemplated plan significantly impacts the operations of the property. For the three and nine months ended September 30, 2026, the Same Property Pool excludes the following: (i) Chastain Market and Founders Square, which were acquired in May 2026, and Village Commons and Legacy West, which were acquired in January and April 2025, respectively; (ii) The Corner – IN, which was reclassified from active development into our operating portfolio in March 2025; (iii) Eastgate Crossing, which was reclassified from our operating portfolio in September 2025 due to significant disruption caused by severe flooding as a result of Tropical Storm Chantal; (iv) our active development projects at One Loudoun; (v) Edwards Multiplex – Ontario, which was reclassified from our operating portfolio into redevelopment in March 2023; (vi) properties sold or classified as held for sale during 2025 and 2026; and (vii) standalone office properties, including the Carillon medical office building.

Kite Realty Group Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) (dollars in thousands) (unaudited)
	Three Months Ended September 30, 2026
Net loss	$	(13,624	)
Depreciation and amortization		79,655
Interest expense		31,569
Income tax expense of taxable REIT subsidiaries		251
EBITDA		97,851
Unconsolidated EBITDA, as adjusted		13,103
Impairment charges		30,694
Gain on sales of operating properties, net		(2,341	)
Other income and expense, net		(30	)
Adjusted EBITDA	$	139,277
Annualized Adjusted EBITDA(1)	$	557,108
Company share of Net Debt:
Mortgage and other indebtedness, net	$	2,807,320
Add: Company share of unconsolidated joint venture debt		270,431
Add: debt discounts, premiums and issuance costs, net		10,500
Less: Partner share of consolidated joint venture debt(2)		(88	)
Company’s consolidated debt and share of unconsolidated debt		3,088,163
Less: cash and cash equivalents		(32,542	)
Less: restricted cash and escrow deposits		(124,527	)
Less: Company share of unconsolidated joint venture cash and cash equivalents		(17,066	)
Company share of Net Debt	$	2,914,028
Net Debt to Adjusted EBITDA	5.2x

(1) Represents Adjusted EBITDA for the three months ended September 30, 2026 (as shown in the table above) multiplied by four.
(2) Partner share of consolidated joint venture debt is calculated based upon the partner’s pro rata ownership of the joint venture, multiplied by the related secured debt balance.

The Company defines EBITDA, a non-GAAP financial measure, as net income before interest expense, income tax expense of the taxable REIT subsidiaries, and depreciation and amortization. For informational purposes, the Company also provides Adjusted EBITDA, which it defines as EBITDA adjusted for (i) EBITDA from unconsolidated entities, as adjusted, (ii) gains on sales of operating properties or impairment charges, (iii) merger and acquisition costs, (iv) other income and expense, (v) noncontrolling interest Adjusted EBITDA, and (vi) other non-recurring activity or items impacting comparability from period to period. Annualized Adjusted EBITDA is Adjusted EBITDA for the most recent quarter multiplied by four. Net Debt to Adjusted EBITDA is the Company’s share of net debt divided by Annualized Adjusted EBITDA. EBITDA, Adjusted EBITDA, Annualized Adjusted EBITDA, and Net Debt to Adjusted EBITDA, as calculated by the Company, are not comparable to EBITDA and EBITDA-related measures reported by other REITs that do not define EBITDA and EBITDA-related measures exactly as we do. EBITDA, Adjusted EBITDA, and Annualized Adjusted EBITDA do not represent cash generated from operating activities in accordance with GAAP and should not be considered alternatives to net income as an indicator of performance or as alternatives to cash flows from operating activities as an indicator of liquidity.

Considering the nature of our business as a real estate owner and operator, the Company believes that EBITDA, Adjusted EBITDA, and the ratio of Net Debt to Adjusted EBITDA are helpful to investors in measuring our operational performance because they exclude various items included in net income that do not relate to or are not indicative of our operating performance, such as gains or losses from sales of depreciated property and depreciation and amortization, which can make periodic and peer analyses of operating performance more difficult. For informational purposes, the Company also provides Annualized Adjusted EBITDA, adjusted as described above. The Company believes this supplemental information provides a meaningful measure of its operating performance. The Company believes presenting EBITDA and the related measures in this manner allows investors and other interested parties to form a more meaningful assessment of the Company’s operating results.

Contact Information: Kite Realty Group
Cooper Clark
VP, Capital Markets & Investor Relations
773.980.0213
coclark@kiterealty.com 

INDIANAPOLIS, Oct. 30, 2026 (GLOBE NEWSWIRE) — Kite Realty Group (NYSE: KRG), a premier owner and operator of high-quality, open-air grocery-anchored shopping centers and vibrant mixed-use assets, reported today its operating results for the third quarter ended September 30, 2026. For the quarters ended September 30, 2026 and 2025, net loss attributable to common shareholders was $13.3 million, or $0.07 per diluted share, compared to $16.2 million, or $0.07 per diluted share, respectively. For the nine months ended September 30, 2026 and 2025, net income attributable to common shareholders was $159.4 million, or $0.78 per diluted share, compared to $117.8 million, or $0.54 per diluted share, respectively.

   Company raises 2026 FFO and Same Property NOI guidance ranges
   Executed over 1.2 million square feet of leasing volume
   Increased signed-not-open NOI pipeline to approximately $38.8 million
Received a credit rating upgrade to BBB+ from Fitch Ratings

“Third quarter results reflect exceptional tenant demand, the quality of our portfolio, and disciplined capital allocation,” said John A. Kite, Chairman and Chief Executive Officer. “We delivered 3.6% Same Property NOI growth and executed over 1.2 million square feet of leasing, including comparable blended lease spreads of 14.6%. This strong leasing volume increased our signed-not-open NOI pipeline to nearly $39 million and boosted our leased-to-occupied spread to an all-time high of 360 basis points. We continued to advance our capital allocation initiatives during the quarter while earning a BBB+ credit rating upgrade from Fitch, further validating the strength of our portfolio and balance sheet.”

Third Quarter 2026 Financial and Operational Results

• Generated Core FFO of the Operating Partnership of $107.0 million, or $0.52 per diluted share.
• Generated NAREIT FFO of the Operating Partnership of $107.9 million, or $0.53 per diluted share.
• Same Property NOI increased by 3.6%.
• Executed 160 new and renewal leases representing approximately 1.2 million square feet.
  • Blended cash leasing spreads of 14.6% on 129 comparable leases, including 33.7% on 30 comparable new leases, 18.3% on 43 comparable non-option renewals, and 7.6% on 56 comparable option renewals.
  • Blended cash leasing spreads of 26.2% for comparable new and non-option renewal leases.
• Operating retail portfolio annualized base rent (ABR) per square foot of $23.52 at September 30, 2026, a 6.4% increase year-over-year.
• Retail portfolio leased percentage of 95.3% at September 30, 2026, a 140-basis point increase year-over-year.
  • Anchor leased percentage of 96.9% at September 30, 2026, a 190-basis point increase year-over-year.
  • Small shop leased percentage of 92.7% at September 30, 2026, a 90-basis point increase year-over-year.
• Portfolio leased-to-occupied spread at period end of 360 basis points, which represents approximately $38.8 million of signed-not-open NOI.

Third Quarter 2026 Capital Allocation Activity

• As previously announced, sold one non-core asset – Tysons Corner in Vienna, VA – for $25.9 million.
  • Subsequent to quarter end, sold one non-core asset – Carillon medical office building in Largo, MD – for a gross sales price of $33.2 million.
• Acquired the fee interest in the land at Pelham Manor Shopping Plaza, an existing retail property in the New York metropolitan statistical area, for a gross purchase price of $52.0 million.
• Repurchased approximately 2.4 million common shares, at an average price of $26.61 per share, for $63.4 million.
  • In 2025 and to date in 2026, repurchased a total of approximately 22.0 million common shares, at an average price of approximately $24.46 per share, for $539.1 million.

Third Quarter 2026 Balance Sheet Overview

• As of September 30, 2026, the Company’s net debt to Adjusted EBITDA was 5.2x.
• As previously announced, on July 2, 2026, the Company’s operating partnership issued $345 million of 3.25% exchangeable senior notes due 2032, which included the full exercise of the initial purchasers’ $45 million overallotment option.
  • In connection with the issuance of the exchangeable notes, the Company entered into capped call transactions with an initial cap of $41.91 per share, compared with the exchangeable notes’ initial exchange price of approximately $35.40 per share. The Company used the majority of the proceeds, together with cash from its recent asset dispositions, to redeem the operating partnership’s $300 million principal balance of the 4.00% senior unsecured notes that were scheduled to mature on October 1, 2026.
• Repaid the $100 million principal balance of the 4.08% senior unsecured notes that matured on September 30, 2026.
• Fitch Ratings upgraded the Company’s corporate credit rating to BBB+ from BBB with a stable rating outlook.

Dividend

• On October 29, 2026, the Company’s Board of Trustees declared a fourth quarter 2026 dividend of $0.29 per common share. Total dividends declared for 2026 of $1.16 per common share represents a 5.5% increase year-over-year. The fourth quarter dividend will be paid on or about January 15, 2027, to shareholders of record as of January 9, 2027.

2026 Earnings Guidance
The Company expects to generate net income of $0.88 to $0.92 per diluted share in 2026. The Company is raising its 2026 Core FFO and NAREIT FFO guidance ranges to $2.08 to $2.12 per diluted share from $2.06 to $2.12 per diluted share, based, in part, on the following full year 2026 assumptions:

• 2026 Same Property NOI growth range of 3.40% to 3.90% (previously 3.00% to 4.00%).
• Bad debt reserve of 0.90% of total revenues at the midpoint.
• Interest expense, net of interest income, excluding unconsolidated joint ventures, of $116.4 million at the midpoint (previously $114.7 million).

The following table reconciles the Company’s 2026 net income guidance range to the Company’s 2026 NAREIT and Core FFO guidance ranges:

		Low			High
Net income		$0.88			$0.92
Gain on sales of operating properties, net			(0.44)			(0.44)
Gain on deconsolidation of joint venture			(0.29)			(0.29)
Impairment charges			0.18			0.18
Depreciation and amortization			1.75			1.75
NAREIT FFO		$2.08			$2.12
Non-cash items			0.00			0.00
Core FFO		$2.08			$2.12

Earnings Conference Call

Kite Realty Group will conduct a conference call to discuss its financial results on Friday, October 30, 2026, at 11:00 a.m. Eastern Time. A live webcast of the conference call will be available on KRG’s website at kiterealty.com or at the following link: KRG Third Quarter 2026 Webcast. The dial-in registration link is: KRG Third Quarter 2026 Teleconference Registration. In addition, a webcast replay link will be available on KRG’s website.

About Kite Realty Group

Kite Realty Group (NYSE: KRG) is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of open-air shopping centers and mixed-use destinations. The Company’s portfolio is concentrated in high-growth Sun Belt and select strategic gateway markets. Publicly listed since 2004, KRG brings more than six decades of experience in developing, operating, and investing in real estate, using a disciplined, hands-on approach to enhance portfolio quality and maximize long-term value for all stakeholders. As of September 30, 2026, the Company owned interests in 164 U.S. open-air shopping centers and mixed-use assets, comprising approximately 26.3 million square feet of gross leasable space. For more information, please visit kiterealty.com.

Connect with KRG: LinkedIn | X | Instagram | Facebook

Safe Harbor

This release, together with other statements and information publicly disseminated by us, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on assumptions and expectations that may not be realized and are inherently subject to risks, uncertainties and other factors, many of which cannot be predicted with accuracy and some of which might not even be anticipated. Future events and actual results, performance, transactions or achievements, financial or otherwise, may differ materially from the results, performance, transactions or achievements, financial or otherwise, expressed or implied by the forward-looking statements.

Risks, uncertainties and other factors that might cause such differences, some of which could be material, include but are not limited to: economic, business, banking, real estate and other market conditions, particularly in connection with low or negative growth in the U.S. economy as well as economic uncertainty (including from an economic slowdown or recession, federal government shutdown, disruptions related to tariffs and other trade or sanction issues, geopolitical instability, rising interest rates, inflation, unemployment, or limited growth in consumer income or spending); financing risks, including the availability of, and costs associated with, sources of liquidity; the Company’s ability to refinance, or extend the maturity dates of, the Company’s indebtedness; the level and volatility of interest rates; the financial stability of the Company’s tenants; the competitive environment in which the Company operates, including potential oversupplies of, or a reduction in demand for, rental space; acquisition, disposition, development and joint venture risks, including the ability to complete them on the terms and timing anticipated; property ownership and management risks, including the relative illiquidity of real estate investments, and expenses, vacancies or the inability to rent space on favorable terms or at all; the Company’s ability to maintain the Company’s status as a real estate investment trust for U.S. federal income tax purposes; potential environmental and other liabilities; impairment in the value of real estate property the Company owns; the attractiveness of our properties to tenants; the actual and perceived impact of e-commerce on the value of shopping center assets and changing demographics and customer traffic patterns; business continuity disruptions and a deterioration in our tenants’ ability to operate in affected areas or delays in the supply of products or services to us or our tenants from vendors that are needed to operate efficiently; risks related to our current geographical concentration of properties in the states of Texas, Florida, and North Carolina and the metropolitan statistical areas of New York, Atlanta, Seattle, Chicago, and Washington, D.C.; civil unrest, acts of violence, terrorism or war, acts of God, climate change, epidemics, pandemics, natural disasters and severe weather conditions, including such events that may result in underinsured or uninsured losses or other increased costs and expenses; changes in laws and government regulations, including governmental orders affecting the use of the Company’s properties or the ability of its tenants to operate, and the costs of complying with such changed laws and government regulations; possible changes in consumer behavior due to public health crises and the fear of future pandemics; our ability to satisfy environmental, social or governance standards set by various constituencies; insurance costs and coverage, especially in Florida and Texas coastal areas and North Carolina; risks associated with cyberattacks and the loss of confidential information and other business disruptions; risks associated with the use of artificial intelligence and related tools; other factors affecting the real estate industry generally; and other risks identified in reports the Company files with the Securities and Exchange Commission or in other documents that it publicly disseminates, including, in particular, the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in the Company’s quarterly reports on Form 10-Q. The Company undertakes no obligation to publicly update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

This Earnings Release also includes certain forward-looking non-GAAP information. These non-GAAP financial measures should be considered along with, but not as alternatives to, net income (loss) as a measure of our operating performance. Please see the following pages for the corresponding definitions and reconciliations of such non-GAAP financial measures.

Kite Realty Group Consolidated Balance Sheets (dollars in thousands) (unaudited)
	September 30, 2026				December 31, 2025
Assets:
Investment properties, at cost	$	6,869,869			$	7,003,479
Less: accumulated depreciation		(1,759,251	)			(1,656,191	)
Net investment properties		5,110,618				5,347,288
Cash and cash equivalents		32,542				36,761
Tenant and other receivables, including accrued straight-line rent of $74,817 and $70,940, respectively		131,237				127,865
Restricted cash and escrow deposits		124,527				441,605
Deferred costs, net		163,121				181,553
Prepaid and other assets		64,970				93,913
Investments in unconsolidated joint ventures		401,162				364,407
Assets associated with investment properties held for sale		—				71,105
Total assets	$	6,028,177			$	6,664,497
Liabilities and Equity:
Liabilities:
Mortgage and other indebtedness, net	$	2,807,320			$	3,025,478
Accounts payable and accrued expenses		178,079				221,118
Deferred revenue and other liabilities		170,079				221,813
Liabilities associated with investment properties held for sale		—				4,314
Total liabilities		3,155,478				3,472,723
Commitments and contingencies
Limited Partners’ interests in the Operating Partnership		129,456				116,245
Equity:
Common shares, $0.01 par value, 490,000,000 shares authorized, 197,966,711 and 208,979,900 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively		1,979				2,090
Additional paid-in capital		4,300,836				4,612,280
Accumulated other comprehensive income		18,576				23,079
Accumulated deficit		(1,578,846	)			(1,563,840	)
Total shareholders’ equity		2,742,545				3,073,609
Noncontrolling interests		698				1,920
Total equity		2,743,243				3,075,529
Total liabilities and equity	$	6,028,177			$	6,664,497

Kite Realty Group Consolidated Statements of Operations (dollars in thousands, except per share amounts) (unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Revenue:
Rental income	$	186,511			$	202,193			$	577,867			$	632,547
Other property-related revenue		1,248				1,477				4,173				4,312
Fee income		2,516				1,291				5,190				2,569
Total revenue		190,275				204,961				587,230				639,428
Expenses:
Property operating		27,653				28,536				87,264				87,243
Real estate taxes		23,666				25,678				72,968				80,090
General, administrative and other		15,041				14,183				43,534				39,831
Depreciation and amortization		79,655				89,370				243,750				285,488
Impairment charges		30,694				39,305				37,562				39,305
Total expenses		176,709				197,072				485,078				531,957
Other (expense) income:
Interest expense		(31,569	)			(33,162	)			(95,008	)			(100,168	)
Income tax expense of taxable REIT subsidiaries		(251	)			(106	)			(1,072	)			(315	)
Gain on sales of operating properties, net		2,341				5,742				90,068				108,855
Net gains from outlot sales		2,259				6,096				4,662				6,096
Gain on deconsolidation of joint venture		—				—				60,625				—
Equity in loss of unconsolidated joint ventures		(3,775	)			(4,619	)			(7,335	)			(8,464	)
Other income, net		3,805				1,750				9,546				6,978
Net (loss) income		(13,624	)			(16,410	)			163,638				120,453
Net loss (income) attributable to noncontrolling interests		322				203				(4,242	)			(2,612	)
Net (loss) income attributable to common shareholders	$	(13,302	)		$	(16,207	)		$	159,396			$	117,841
Net (loss) income per common share – basic	$	(0.07	)		$	(0.07	)		$	0.79			$	0.54
Net (loss) income per common share – diluted	$	(0.07	)		$	(0.07	)		$	0.78			$	0.54
Weighted average common shares outstanding – basic		199,097,852				219,408,533				202,314,395				219,652,052
Weighted average common shares outstanding – diluted		199,097,852				219,408,533				203,142,324				219,768,504

Kite Realty Group NAREIT Funds From Operations (“FFO”)(1) (dollars in thousands, except per share amounts) (unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Net (loss) income	$	(13,624	)		$	(16,410	)		$	163,638			$	120,453
Less: net income attributable to noncontrolling interests in properties		—				(82	)			(126	)			(233	)
Less: gain on sales of operating properties, net		(2,341	)			(5,742	)			(90,068	)			(108,855	)
Less: gain on deconsolidation of joint venture		—				—				(60,625	)			—
Add: impairment charges		30,694				39,305				37,562				39,305
Add: depreciation and amortization of consolidated and unconsolidated entities, net of noncontrolling interests		93,163				101,750				275,983				304,896
NAREIT FFO of the Operating Partnership(1)		107,892				118,821				326,364				355,566
Less: Limited Partners’ interests in FFO		(2,800	)			(2,569	)			(8,212	)			(7,498	)
FFO attributable to common shareholders(1)	$	105,092			$	116,252			$	318,152			$	348,068
FFO, as defined by NAREIT, per share of the Operating Partnership – basic	$	0.53			$	0.53			$	1.57			$	1.58
FFO, as defined by NAREIT, per share of the Operating Partnership – diluted	$	0.53			$	0.53			$	1.57			$	1.58
Weighted average common shares outstanding – basic		199,097,852				219,408,533				202,314,395				219,652,052
Weighted average common shares outstanding – diluted		199,199,751				219,531,606				202,410,018				219,768,504
Weighted average common shares and units outstanding – basic		204,405,613				224,258,121				207,539,183				224,386,126
Weighted average common shares and units outstanding – diluted		204,507,512				224,381,194				207,634,806				224,502,578
Reconciliation of NAREIT FFO to Core FFO(2)
NAREIT FFO of the Operating Partnership(1)	$	107,892			$	118,821			$	326,364			$	355,566
Add:
Amortization of deferred financing costs		2,220				1,856				5,877				5,251
Non-cash compensation expense and other		3,679				3,084				10,568				8,965
Less:
Straight-line rent – minimum rent and common area maintenance		2,850				3,789				7,970				9,202
Market rent amortization income		3,091				2,500				7,433				7,921
Amortization of debt discounts, premiums and hedge instruments		826				1,030				2,885				4,676
Core FFO of the Operating Partnership	$	107,024			$	116,442			$	324,521			$	347,983
Core FFO per share of the Operating Partnership – diluted	$	0.52			$	0.52			$	1.56			$	1.55

(1) “NAREIT FFO of the Operating Partnership” measures 100% of the operating performance of the Operating Partnership’s real estate properties. “FFO attributable to common shareholders” reflects a reduction for the redeemable noncontrolling weighted average diluted interest in the Operating Partnership.

(2) Includes the Company’s pro rata share from unconsolidated joint ventures.

NAREIT Funds From Operations (“FFO”) is a widely used performance measure for real estate companies and is provided here as a supplemental measure of our operating performance. The Company calculates FFO, a non-GAAP financial measure, in accordance with the best practices described in the April 2002 National Policy Bulletin of the National Association of Real Estate Investment Trusts (“NAREIT”), as restated in 2018. The NAREIT white paper defines FFO as net income (calculated in accordance with GAAP), excluding (i) depreciation and amortization related to real estate, (ii) gains and losses from the sale of certain real estate assets, (iii) gains and losses from change in control, and (iv) impairment write-downs of certain real estate assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity.

Considering the nature of our business as a real estate owner and operator, the Company believes that FFO is helpful to investors in measuring our operational performance because it excludes various items included in net income that do not relate to or are not indicative of our operating performance, such as gains or losses from sales of certain real estate assets that are excluded from FFO under the NAREIT definition and depreciation and amortization, which can make periodic and peer analyses of operating performance more difficult. FFO (a) should not be considered as an alternative to net income (calculated in accordance with GAAP) for the purpose of measuring our financial performance, (b) is not an alternative to cash flows from operating activities (calculated in accordance with GAAP) as a measure of our liquidity, and (c) is not indicative of funds available to satisfy our cash needs, including our ability to make distributions. The Company’s computation of FFO may not be comparable to FFO reported by other REITs that do not define the term in accordance with the current NAREIT definition or that interpret the current NAREIT definition differently than we do.

From time to time, the Company may report or provide guidance with respect to “FFO, as adjusted,” which removes the impact of certain non-recurring and non-operating transactions or other items the Company does not consider to be representative of its core operating results, including, without limitation, (i) gains or losses associated with the early extinguishment of debt, (ii) gains or losses associated with litigation involving the Company that is not in the normal course of business, (iii) merger and acquisition costs, (iv) the impact on earnings from significant and non-recurring employee severance costs and recruiting expenses, including sign-on bonuses and search fees, (v) the excess of redemption value over carrying value of preferred stock redemption, and (vi) the impact of prior period bad debt or the collection of accounts receivable previously written off (“prior period collection impact”), which are not otherwise adjusted in the Company’s calculation of FFO.

Core Funds From Operations (“Core FFO”) is a non-GAAP financial measure of operating performance that modifies FFO for certain non-cash transactions that result in recording income or expense and impact the Company’s period-over-period performance, including (i) amortization of deferred financing costs, (ii) non-cash compensation expense and other, (iii) straight-line rent related to minimum rent and common area maintenance, (iv) market rent amortization income, and (v) amortization of debt discounts, premiums and hedge instruments, and includes adjustments related to our pro rata share from unconsolidated joint ventures for these categories as applicable. The Company believes that Core FFO is useful to investors in evaluating the core cash flow-generating operations of the Company by adjusting for items that we do not consider to be part of our core business operations, allowing for comparison of core operating performance of the Company between periods. Core FFO should not be considered as an alternative to net income as an indicator of the Company’s performance or as an alternative to cash flow as a measure of liquidity or the Company’s ability to make distributions. The Company’s computation of Core FFO may differ from the methodology for calculating Core FFO used by other REITs and, therefore, may not be comparable to such other REITs.

Kite Realty Group
Same Property Net Operating Income (“NOI”)
(dollars in thousands)
(unaudited)
	Three Months Ended September 30,											Nine Months Ended September 30,
		2026				2025			Change				2026				2025			Change
Number of properties in Same Property Pool for the period(1)		157				157							157				157
Leased percentage at period end		95.2	%			94.4	%						95.2	%			94.4	%
Economic occupancy percentage at period end		91.5	%			91.7	%						91.5	%			91.7	%
Economic occupancy percentage(2)		91.3	%			91.1	%						91.1	%			91.4	%
Minimum rent	$	139,166			$	135,581						$	415,600			$	404,014
Tenant recoveries		40,226				37,994							122,725				115,216
Bad debt reserve		(1,628	)			(1,947	)						(4,685	)			(5,219	)
Overage rent		1,560				1,282							4,386				3,840
Other property-related revenue		896				789							2,630				2,212
Total revenue		180,220				173,699							540,656				520,063
Property operating		(25,027	)			(24,241	)						(75,801	)			(71,700	)
Real estate taxes		(23,176	)			(21,974	)						(69,363	)			(67,158	)
Total expenses		(48,203	)			(46,215	)						(145,164	)			(138,858	)
Same Property NOI(3)	$	132,017			$	127,484			3.6	%		$	395,492			$	381,205			3.7	%
Reconciliation of Same Property NOI to most directly comparable GAAP measure:
Net operating income – same properties	$	132,017			$	127,484						$	395,492			$	381,205
Net operating income – sold properties		152				18,700							15,697				74,230
Net operating income – non-same activity(4)		6,972				5,756							18,558				17,309
Less: KRG share of unconsolidated joint ventures included in Same Property NOI above		(2,701	)			(2,484	)						(7,939	)			(3,218	)
Net gains from outlot sales		2,259				6,096							4,662				6,096
Total property NOI		138,699				155,552			(10.8	%)			426,470				475,622			(10.3	%)
Fee income		2,516				1,291							5,190				2,569
General, administrative and other		(15,041	)			(14,183	)						(43,534	)			(39,831	)
Depreciation and amortization		(79,655	)			(89,370	)						(243,750	)			(285,488	)
Impairment charges		(30,694	)			(39,305	)						(37,562	)			(39,305	)
Interest expense		(31,569	)			(33,162	)						(95,008	)			(100,168	)
Income tax expense of taxable REIT subsidiaries		(251	)			(106	)						(1,072	)			(315	)
Gain on sales of operating properties, net		2,341				5,742							90,068				108,855
Gain on deconsolidation of joint venture		—				—							60,625				—
Equity in loss of unconsolidated joint ventures		(3,775	)			(4,619	)						(7,335	)			(8,464	)
Other income, net		3,805				1,750							9,546				6,978
Net loss (income) attributable to noncontrolling interests		322				203							(4,242	)			(2,612	)
Net (loss) income attributable to common shareholders	$	(13,302	)		$	(16,207	)					$	159,396			$	117,841

(1)   Same Property NOI excludes the following: (i) Chastain Market and Founders Square, which were acquired in May 2026, and Village Commons and Legacy West, which were acquired in January and April 2025, respectively; (ii) The Corner – IN, which was reclassified from active development into our operating portfolio in March 2025; (iii) Eastgate Crossing, which was reclassified from our operating portfolio in September 2025 due to significant disruption caused by severe flooding as a result of Tropical Storm Chantal; (iv) our active development projects at One Loudoun; (v) Edwards Multiplex – Ontario, which was reclassified from our operating portfolio into redevelopment in March 2023; (vi) properties sold or classified as held for sale during 2025 and 2026; and (vii) standalone office properties, including the Carillon medical office building.
(2)   Excludes leases that are signed but for which tenants have not yet commenced the payment of cash rent. Calculated as a weighted average based on the timing of cash rent commencement and expiration during the period.
(3)   Same Property NOI for all periods presented includes (i) 52% of the NOI from three previously wholly owned properties that were contributed to the Seed Asset Joint Venture in June 2025 and (ii) 55% of the NOI from the One Loudoun Phase 1 Apartments (which 55% represents the Company’s expected final ownership percentage) and excludes the results of the Company’s insurance captive.
(4)   Includes non-cash activity as well as NOI from properties not included in the Same Property Pool.

The Company uses NOI, a non-GAAP financial measure, to evaluate the performance of our properties. The Company also uses total property NOI, which is defined as NOI plus net gains from outlot sales. The Company defines NOI as income from our real estate, including lease termination fees received from tenants, less our property operating expenses. NOI excludes amortization of capitalized tenant improvement costs and leasing commissions and certain corporate-level expenses, including merger and acquisition costs. The Company believes that NOI is helpful to investors as a measure of our operating performance because it excludes various items included in net income that do not relate to or are not indicative of our operating performance, such as depreciation and amortization, interest expense, and impairment, if any.

The Company also uses same property NOI (“Same Property NOI”), a non-GAAP financial measure, to evaluate the performance of our properties. Same Property NOI is net income excluding properties that have not been owned for the full periods presented. Beginning in 2026, the Company revised its Same Property NOI definition to exclude the results of the Company’s insurance captive to more clearly reflect the performance of our core real estate portfolio. Same Property NOI also excludes (i) net gains from outlot sales, (ii) straight-line rent revenue, (iii) lease termination income in excess of lost rent, (iv) amortization of lease intangibles, (v) significant prior period expense recoveries and adjustments, if any, and (vi) income or expense associated with the Company’s captive insurance company. When the Company receives payments in excess of any accounts receivable for terminating a lease, Same Property NOI will include such excess payments as monthly rent until the earlier of the expiration of 12 months or the start date of a replacement tenant.

The Company believes that Same Property NOI is helpful to investors as a measure of our operating performance because it includes only the NOI of properties that have been owned for the full periods presented. The Company believes such presentation eliminates disparities in net income due to the acquisition or disposition of properties during the particular periods presented and thus provides a more consistent metric for the comparison of our properties. Additionally, because results from the Company’s insurance captive are driven by insurance underwriting, loss experience, and actuarial assumptions and therefore do not reflect the operating performance of our real estate properties, management believes excluding the impacts of the insurance captive improves transparency and comparability for the Company’s investors. Same Property NOI includes the results of properties that have been owned for the entire current and prior year reporting periods. Same Property NOI for all periods presented includes (i) 52% of the NOI from three previously wholly owned properties that were contributed to the Seed Asset Joint Venture in June 2025 and (ii) 55% of the NOI from the One Loudoun Phase 1 Apartments (which 55% represents the Company’s expected final ownership percentage) and excludes the results of the Company’s insurance captive.

NOI and Same Property NOI should not, however, be considered as an alternative to net income (calculated in accordance with GAAP) as an indicator of our financial performance. The Company’s computation of NOI and Same Property NOI may differ from the methodology used by other REITs and, therefore, may not be comparable to such other REITs.

When evaluating the properties that are included in the Same Property Pool, we have established specific criteria for determining the inclusion of properties acquired or those recently under development. An acquired property is included in the Same Property Pool when there is a full quarter of operations in both years subsequent to the acquisition date. Development and redevelopment properties are included in the Same Property Pool four full quarters after the properties have been transferred to the operating portfolio. A redevelopment property is first excluded from the Same Property Pool when the execution of a redevelopment plan is likely, and we (a) begin recapturing space from tenants or (b) the contemplated plan significantly impacts the operations of the property. For the three and nine months ended September 30, 2026, the Same Property Pool excludes the following: (i) Chastain Market and Founders Square, which were acquired in May 2026, and Village Commons and Legacy West, which were acquired in January and April 2025, respectively; (ii) The Corner – IN, which was reclassified from active development into our operating portfolio in March 2025; (iii) Eastgate Crossing, which was reclassified from our operating portfolio in September 2025 due to significant disruption caused by severe flooding as a result of Tropical Storm Chantal; (iv) our active development projects at One Loudoun; (v) Edwards Multiplex – Ontario, which was reclassified from our operating portfolio into redevelopment in March 2023; (vi) properties sold or classified as held for sale during 2025 and 2026; and (vii) standalone office properties, including the Carillon medical office building.

Kite Realty Group Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) (dollars in thousands) (unaudited)
	Three Months Ended September 30, 2026
Net loss	$	(13,624	)
Depreciation and amortization		79,655
Interest expense		31,569
Income tax expense of taxable REIT subsidiaries		251
EBITDA		97,851
Unconsolidated EBITDA, as adjusted		13,103
Impairment charges		30,694
Gain on sales of operating properties, net		(2,341	)
Other income and expense, net		(30	)
Adjusted EBITDA	$	139,277
Annualized Adjusted EBITDA(1)	$	557,108
Company share of Net Debt:
Mortgage and other indebtedness, net	$	2,807,320
Add: Company share of unconsolidated joint venture debt		270,431
Add: debt discounts, premiums and issuance costs, net		10,500
Less: Partner share of consolidated joint venture debt(2)		(88	)
Company’s consolidated debt and share of unconsolidated debt		3,088,163
Less: cash and cash equivalents		(32,542	)
Less: restricted cash and escrow deposits		(124,527	)
Less: Company share of unconsolidated joint venture cash and cash equivalents		(17,066	)
Company share of Net Debt	$	2,914,028
Net Debt to Adjusted EBITDA	5.2x

(1) Represents Adjusted EBITDA for the three months ended September 30, 2026 (as shown in the table above) multiplied by four.
(2) Partner share of consolidated joint venture debt is calculated based upon the partner’s pro rata ownership of the joint venture, multiplied by the related secured debt balance.

The Company defines EBITDA, a non-GAAP financial measure, as net income before interest expense, income tax expense of the taxable REIT subsidiaries, and depreciation and amortization. For informational purposes, the Company also provides Adjusted EBITDA, which it defines as EBITDA adjusted for (i) EBITDA from unconsolidated entities, as adjusted, (ii) gains on sales of operating properties or impairment charges, (iii) merger and acquisition costs, (iv) other income and expense, (v) noncontrolling interest Adjusted EBITDA, and (vi) other non-recurring activity or items impacting comparability from period to period. Annualized Adjusted EBITDA is Adjusted EBITDA for the most recent quarter multiplied by four. Net Debt to Adjusted EBITDA is the Company’s share of net debt divided by Annualized Adjusted EBITDA. EBITDA, Adjusted EBITDA, Annualized Adjusted EBITDA, and Net Debt to Adjusted EBITDA, as calculated by the Company, are not comparable to EBITDA and EBITDA-related measures reported by other REITs that do not define EBITDA and EBITDA-related measures exactly as we do. EBITDA, Adjusted EBITDA, and Annualized Adjusted EBITDA do not represent cash generated from operating activities in accordance with GAAP and should not be considered alternatives to net income as an indicator of performance or as alternatives to cash flows from operating activities as an indicator of liquidity.

Considering the nature of our business as a real estate owner and operator, the Company believes that EBITDA, Adjusted EBITDA, and the ratio of Net Debt to Adjusted EBITDA are helpful to investors in measuring our operational performance because they exclude various items included in net income that do not relate to or are not indicative of our operating performance, such as gains or losses from sales of depreciated property and depreciation and amortization, which can make periodic and peer analyses of operating performance more difficult. For informational purposes, the Company also provides Annualized Adjusted EBITDA, adjusted as described above. The Company believes this supplemental information provides a meaningful measure of its operating performance. The Company believes presenting EBITDA and the related measures in this manner allows investors and other interested parties to form a more meaningful assessment of the Company’s operating results.

Contact Information: Kite Realty Group
Cooper Clark
VP, Capital Markets & Investor Relations
773.980.0213
coclark@kiterealty.com 

SANTIAGO, Chile, Oct. 30, 2026 (GLOBE NEWSWIRE) — BANCO ITAÚ CHILE (SSE: ITAUCL) announced today its Management Commentary for the third quarter ended September 30, 2026. For the full report, please refer to the webpage: 

https://ir.itau.cl/results-and-reports/quarterly-reports/

On Monday, November 9, 2026, at 11:00 A.M. Santiago time (9:00 A.M. ET), the Company’s management team will host a conference call to discuss the financial results. The call will be hosted by André Gailey, CEO; Emiliano Muratore, CFO; and Andrés Perez, Chief Economist.

Webinar Details:

Online registration: 

https://mzgroup.zoom.us/webinar/register/WN_slxE0MqmSSSMHGNxWz-hfA    

All participants must pre-register using this link to join the webinar. Upon registering, each participant will be provided with details to connect to the call.

Q&A session:

The Q&A session will be available for participants through the webinar, where attendees will be allowed to present their questions – we will answer selected questions verbally.

Investor Relations – Itaú Chile

IR@itau.cl / ir.itau.cl